Praeruptorin E

Synonyms: 白花前胡素 E
Praeruptorin E 是一种具有口服活性的吡喃香豆素类化合物,可从 Peucedanum praeruptorum Dunn 的干燥根中分离,能降低 NF-κB 表达、上调 PXR 和 CYP3A4 表达、抑制 Th2 细胞因子、TNF-α、IL6、MPO 并阻断 Ca2+ 慢通道,同时促进肺组织修复、舒张猪冠状动脉条、保护小鼠免受脂多糖和盐酸诱导的急性肺损伤,可用于哮喘和急性肺损伤的相关研究。
产品编号: MS-D95817 纯度: 99.18% CAS No.: 78478-28-1 分子式: C24H28O7 分子量: 428.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Praeruptorin E 是一种具有口服活性的吡喃香豆素类化合物,可从 Peucedanum praeruptorum Dunn 的干燥根中分离,能降低 NF-κB 表达、上调 PXR 和 CYP3A4 表达、抑制 Th2 细胞因子、TNF-α、IL6、MPO 并阻断 Ca2+ 慢通道,同时促进肺组织修复、舒张猪冠状动脉条、保护小鼠免受脂多糖和盐酸诱导的急性肺损伤,可用于哮喘和急性肺损伤的相关研究。

生物实验数据

生物活性 Praeruptorin E is an orally active pyranocoumarin compound isolated from the dried roots of Peucedanum praeruptorum Dunn that downregulates NF-κB expression, upregulates PXR and CYP3A4 expression, inhibits Th2 cytokines, TNF-α, IL6, and MPO, and blocks slow Ca2+ channels, while promoting lung tissue repair, relaxing porcine coronary artery strips, and protecting mice against lipopolysaccharide- and hydrochloric acid-induced acute lung injury, and can be used for research related to asthma and acute lung injury.
IC50 & Target

CYP3A4

 

IL-6

 

体外研究
(In Vitro)

Praeruptorin E (60 μM; 24 h) 可降低 LPS 诱导的 L-02 胎肝细胞中 NF-κB p65 的表达,并上调 PXR 和 CYP3A4 的表达,且该作用部分依赖于 PXR 的表达。
Praeruptorin E (60 μM) 可降低 L-02 胎肝细胞中 NF-κB p65 与 PXR 基因启动子的结合,该区域的 NF-κB 富集水平显著降低可证明这一点。
Praeruptorin E (4.7 μM) 可在钾离子去极化的猪冠状动脉条上发挥钙拮抗剂作用,其 pD2 值为 5.2,能够抑制 Ca2+ 诱导的最大收缩,并以非平行方式使 Ca2+ 浓度-反应曲线右移。

体内研究
(In Vivo)

Praeruptorin E (灌胃;每日 1 次;连续 7 天,剂量 2.5-40 mg/kg) 可通过减轻气道炎症、黏液分泌及胶原沉积,增强 Aminophylline (MS-J67700) 对 Ovalbumin (MS-Q48215) 诱导的哮喘小鼠的抗哮喘效果,同时还能降低 Aminophylline 诱导的心脏毒性,其中 40 mg/kg 剂量的作用最强。
Praeruptorin E (20-80 mg/kg;口服;LPS 攻击前 1 小时单次给予) 可剂量依赖性地减轻雄性 BALB/c 小鼠中 LPS 诱导的急性肺损伤,其中 80 mg/kg 剂量对中性粒细胞 (PMNs) 浸润的抑制率达 53%,对 TNF-α 释放的抑制率达 56%,对 IL-6 释放的抑制率达 51%,同时可抑制 NF-κB 通路的激活并改善肺组织病理学改变。
Praeruptorin E (80 mg/kg;口服;盐酸攻击前 1 小时单次给予) 可通过减少中性粒细胞 (PMNs) 浸润、IL-6 释放、蛋白外渗及肺部组织病理学损伤,保护雄性 BALB/c 小鼠免受盐酸诱导的急性肺损伤。

Animal Model: BALB/c (male, 18-22 g, ovalbumin-induced asthma)
Dosage: 2.5 mg/kg; 10 mg/kg; 40 mg/kg
Administration: i.g.; daily; 7 days
Result: Significantly reduced total inflammatory cells, eosinophils, monocytes, neutrophils, and lymphocytes in bronchoalveolar lavage fluid compared to aminophylline alone, with the 40 mg/kg dose showing the greatest reduction.
Significantly lowered lung and bronchial histopathological scores compared to aminophylline alone, with the 40 mg/kg dose showing the least severe pathological changes including reduced inflammatory cell infiltration, alveolar wall thickening, and bronchial mucosal edema.
Significantly reduced mucus secretion (PAS-positive area) and collagen deposition (fibrosis area) in lung tissue compared to aminophylline alone, with the 40 mg/kg dose showing the largest reduction.
Significantly lowered concentrations of BALF IL-4, IL-5, IL-13, serum IgE, and NF-κB p65 compared to aminophylline alone.
Significantly reduced lung tissue NF-κB p65 protein and mRNA expression compared to aminophylline alone, while significantly increased liver tissue PXR and CYP3A11 protein and mRNA expression compared to aminophylline alone.
Showed no significant differences in CYP1A2 and CYP2E1 expression across groups.
Improved heart rhythm regularity, reduced premature ventricular beats, and significantly lowered serum LDH and CK-MB levels compared to aminophylline alone when combined with a high (cardiotoxic) dose of aminophylline (450 mg/kg).
Animal Model: BALB/c (male, 6-8 weeks old, 20-25 g, LPS-induced acute lung injury)
Dosage: 20 mg/kg; 40 mg/kg; 80 mg/kg
Administration: p.o.; single dose 1 hour before LPS challenge
Result: Reduced bronchoalveolar lavage fluid total cell counts from 792×103/mL to 472×103/mL at 80 mg/kg.
Reduced bronchoalveolar lavage fluid PMNs counts from 648×103/mL to 381×103/mL at 80 mg/kg.
Reduced bronchoalveolar lavage fluid TNF-α levels from 6.645 ng/mL to 3.962 ng/mL at 80 mg/kg.
Reduced bronchoalveolar lavage fluid IL-6 levels from 1.096 ng/mL to 0.523 ng/mL at 80 mg/kg.
Caused 11%, 43%, and 53% inhibition of LPS-induced PMNs counts at 20 mg/kg, 40 mg/kg, and 80 mg/kg, respectively.
Achieved 56% inhibition of TNF-α levels and 51% inhibition of IL-6 levels at 80 mg/kg.
Reduced LPS-induced protein extravasation in bronchoalveolar lavage fluid in a dose-dependent manner.
Reduced lung myeloperoxidase (MPO) activity at 80 mg/kg.
Attenuated LPS-induced lung pathological changes including neutrophil infiltration, alveolar wall swelling, hemorrhage, and alveolar structural damage at 80 mg/kg.
Inhibited LPS-induced cytoplasmic loss of IκB-α protein at 80 mg/kg.
Suppressed translocation of NF-κB p65 from cytoplasm to nucleus at 80 mg/kg.
Animal Model: BALB/c (male, 6-8 weeks old, 20-25 g, HCl-induced acute lung injury)
Dosage: 80 mg/kg
Administration: p.o.; single dose 1 hour before HCl challenge
Result: Reduced HCl-induced PMNs counts in bronchoalveolar lavage fluid.
Decreased HCl-induced IL-6 levels in bronchoalveolar lavage fluid.
Inhibited HCl-induced protein extravasation in bronchoalveolar lavage fluid.
Attenuated HCl-induced lung pathological changes including severe hemorrhage, neutrophil infiltration, and alveolar structural damage.
性状 固体
颜色 White to off-white

化学信息

分子量 428.47
分子式 C24H28O7
CAS No. 78478-28-1
别名 白花前胡素 E

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 2.14 mg/mL (4.99 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (58.35 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.3339 mL11.6694 mL23.3389 mL58.3471 mL
5 mM0.4668 mL2.3339 mL4.6678 mL11.6694 mL
10 mM0.2334 mL1.1669 mL2.3339 mL5.8347 mL
15 mM0.1556 mL0.7780 mL1.5559 mL3.8898 mL
20 mM0.1167 mL0.5835 mL1.1669 mL2.9174 mL
25 mM0.0934 mL0.4668 mL0.9336 mL2.3339 mL
30 mM0.0778 mL0.3890 mL0.7780 mL1.9449 mL
40 mM0.0583 mL0.2917 mL0.5835 mL1.4587 mL
50 mM0.0467 mL0.2334 mL0.4668 mL1.1669 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础